cemiplimab (Libtayo®)
Application Details
HSE100123
26036b
cemiplimab
Libtayo®
Regeneron Ireland Designated Activity Company (DAC)
14/07/2026
24/03/2023
Application Status
Rapid Review Completed
17/08/2026
Rapid Review Completed
17/08/2026
Pricing and Reimbursement Application Complete
14/07/2026
Rapid Review Commissioned
10/07/2026